Ella W Mathews,Sydney R Coffey,Annette Gaertner,Jillian Belgrad,Robert M Bragg,Daniel O'Reilly,Jeffrey P Cantle,Cassandra McHugh,Ashley Summers,Joachim Fentz,Tom Schwagarus,Antje Cornelius,Ioannis Lingos,Zoe Burch,Marina Kovalenko,Marissa A Andrew,C. Frank Bennett,Holly Kordasiewicz,Deanna M Marchionini,Hilary Wilkinson,Thomas F Vogt,Richard M Pinto,Anastasia Khvorova,David Howland,Vanessa Wheeler,Jeffrey Brian Carroll

Abstract:Huntington's disease (HD) arises from a CAG expansion in the huntingtin (HTT) gene beyond a critical threshold. A major thrust of current HD therapeutic development is lowering levels of mutant HTT mRNA (mHTT) and protein (mHTT) with the aim of reducing the toxicity of these product(s). Human genetic data also support a key role for somatic instability (SI) in HTT's CAG repeat -- whereby it lengthens with age in specific somatic cell types -- as a key driver of age of motor dysfunction onset. Thus, an attractive HD therapy would address both mHTT toxicity and SI, but to date the relationship between SI and HTT lowering remains unexplored. Here, we investigated multiple therapeutically-relevant HTT-lowering modalities to establish the relationship between HTT lowering and SI in HD knock-in mice. We find that repressing transcription of mutant Htt (mHtt) provides robust protection from SI, using diverse genetic and pharmacological approaches (antisense oligonucleotides, CRISPR-Cas9 genome editing, the Lac repressor, and virally delivered zinc finger transcriptional repressor proteins, ZFPs). However, we find that small interfering RNA (siRNA), a potent HTT-lowering treatment, lowers HTT levels without influencing SI and that SI is also normal in mice lacking 50% of total HTT levels, suggesting HTT levels, per se, do not modulate SI in trans. Remarkably, modified ZFPs that bind the mHtt locus, but lack a repressive domain, robustly protect from SI, despite not reducing HTT mRNA or protein levels. These results have important therapeutic implications in HD, as they suggest that DNA-targeted HTT-lowering treatments may have significant advantages compared to other HTT-lowering approaches, and that interaction of a DNA-binding protein and HTT's CAG repeats may provide protection from SI while sparing HTT expression.

Gene Targeting Techniques for Huntington’s Disease

Progress in studies of gene therapy for Huntington's disease

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease

Using gene or cell therapies to treat Huntington's disease

Advances in Gene and Cellular Therapeutic Approaches for Huntington’s Disease

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

CRISPR-Based Genome-Editing Tools for Huntington’s Disease Research and Therapy

Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies

Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease

Molecular Strategies to Target Protein Aggregation in Huntington's Disease

Suppression of Huntington's Disease Somatic Instability by Transcriptional Repression and Direct CAG Repeat Binding

Complex Pathogenesis and Therapeutic Strategies

Sequencing-Guided Design of Genetically Encoded Small RNAs Targeting CAG Repeats for Selective Inhibition of Mutant Huntingtin

In vivo CRISPR base editing for treatment of Huntington′s disease

Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics

Spliceosome-mediated RNA &Lt;i>trans</i>-Splicing: a Strategy for Huntington’s Disease Gene Therapy

Preclinical evaluation of stereopure antisense oligonucleotides for allele-selective lowering of mutant HTT

Identification of genetic modifiers of Huntington's disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

Identification of genetic modifiers of Huntington′s disease somatic CAG repeat instability by in vivo CRISPR-Cas9 genome editing

RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA

Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin